... Mirvetuximab Soravtansine-GynxApproved in 2022, mirvetuximab soravtansine-gynx (Elahere) is used for people with platinum-resistant ovarian cancer that tests high for folate receptor alpha (FR-alpha) and who have had one to three prior treatments. ...
... Food and Drug Administration Targeted Therapy for Ovarian Cancer — American Cancer Society Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers — National Cancer Institute Survival Rates for Ovarian Cancer — American Cancer Society ...
Stage 3 Ovarian Cancer Explained
... Food and Drug Administration Targeted Therapy for Ovarian Cancer — American Cancer Society Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers — National Cancer Institute Survival Rates for Ovarian Cancer — American Cancer Society ...
... It’s called mirvetuximab soravtansine-gynx (Elahere). Mirvetuximab soravtansine-gynx received accelerated approval in 2022 after positive results were published from clinical trials. ...
... Mirvetuximab soravtansine (Elahere) is an antibody-drug conjugate (ADC). This means it combines a chemotherapy drug with a lab-made antibody that helps deliver the drug directly to cancer cells.According to the American Cancer Society, ovarian cancers often have high levels of folate receptor-alpha (FR-alpha) proteins. ...
6 Ovarian Cancer Treatment Options
... Mirvetuximab soravtansine (Elahere) is an antibody-drug conjugate (ADC). This means it combines a chemotherapy drug with a lab-made antibody that helps deliver the drug directly to cancer cells.According to the American Cancer Society, ovarian cancers often have high levels of folate receptor-alpha (FR-alpha) proteins. ...
... Cancer Society Abdominal Adhesions: A Practical Review of an Often Overlooked Entity — Annals of Medicine and Surgery Treating the Symptoms of Advanced Ovarian Cancer — Cancer Research UK Edema (Swelling) — American Cancer Society Ifosfamide (Intravenous Route) — Mayo Clinic Chemobrain — The University of Texas MD Anderson Cancer Center Approval of Elahere ...
15 Complications of Advanced Ovarian Cancer Treatments
... Cancer Society Abdominal Adhesions: A Practical Review of an Often Overlooked Entity — Annals of Medicine and Surgery Treating the Symptoms of Advanced Ovarian Cancer — Cancer Research UK Edema (Swelling) — American Cancer Society Ifosfamide (Intravenous Route) — Mayo Clinic Chemobrain — The University of Texas MD Anderson Cancer Center Approval of Elahere ...
... One drug in this category is called mirvetuximab soravtansine-gynx (Elahere). It was approved in 2024 to treat platinum-resistant epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer.A newer targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, was approved in 2025. ...
Recurrent Ovarian Cancer Explained
... One drug in this category is called mirvetuximab soravtansine-gynx (Elahere). It was approved in 2024 to treat platinum-resistant epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer.A newer targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, was approved in 2025. ...
... Because ADCs are targeted just toward the cancerous cells, they cause fewer side effects than chemotherapy.One ADC is called mirvetuximab soravtansine-gynx (Elahere). In 2024, this drug was approved to treat platinum-resistant epithelial ovarian cancer that tests positive for a protein called folate receptor-alpha. ...
Platinum Resistance in Ovarian Cancer Treatment: What You Need To Know
... Because ADCs are targeted just toward the cancerous cells, they cause fewer side effects than chemotherapy.One ADC is called mirvetuximab soravtansine-gynx (Elahere). In 2024, this drug was approved to treat platinum-resistant epithelial ovarian cancer that tests positive for a protein called folate receptor-alpha. ...
... Drugs in the PARP inhibitor family include olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula).Mirvetuximab soravtansine-gynx (Elahere) is a newer targeted therapy option. This drug is a type of antibody drug conjugate. ...
Join
